Strides Pharma Share Price Surges 3%; Receives USFDA EIR for Bengaluru Facility

Strides Pharma Science has got the Establishment Inspection Report (EIR) from the USFDA for its Bengaluru plant, as per the exchange filings. 

The USFDA had inspected the facility from May 12 to May 20, 2026. Five observations were made during the inspection and were listed in a Form 483.  

Company Responded to the Observations 

After the inspection, Strides Pharma submitted its response to all five observations within the given time. 

The company also took corrective and preventive steps to address the points raised during the inspection.  

USFDA Gives VAI Classification 

After checking the company's response and the steps taken, the USFDA classified the inspection result as Voluntary Action Indicated (VAI). The USFDA then issued the EIR, which brought the inspection to an end.  

Bengaluru Plant Makes Different Medicines 

The Bengaluru facility is one of Strides Pharma's main manufacturing plants. It supplies medicines to regulated and other international markets. 

The plant makes tablets, capsules and oral liquids. These include products that are already being sold as well as products that can support the company's future business.  

About Strides Pharma 

Strides Pharma is a pharmaceutical company based in Bengaluru. It mainly works in regulated markets and also has an “in Africa for Africa” business strategy. 

The company has manufacturing facilities in India, Italy, Kenya and the US. Its products are sold in more than 100 countries.  

Read More: Government Approves 31 Electronics Component Projects Worth ₹7,877 Crore Across 10 States! 

Strides Pharma Share Price Performance 

As of August 20, 2026, at 1:33 PM, Strides Pharma share price was trading at ₹990.00 per share, reflecting a surge of 3.39% from the previous trading session. 

Conclusion 

Strides Pharma has received the USFDA's EIR for its Bengaluru plant. The inspection had five observations, and the company later responded to them and took corrective steps before the USFDA closed the inspection.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Take action on today’s market news - Complete your Demat Account Opening now.